GILD

Gilead Sciences, Inc.

Healthcare · $185.0B market cap

Share price

$144.74

close of Oct 3, 2026

Fair value

$113.70

Sticker Price

Payback Price

$45.48

buy price

Overpriced

GILD is Overpriced: at $144.74 it trades 27% above its fair value of $113.70. Its buy price (Payback Price) is $45.48, 69% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.

How we valued it

Dividend Discount Model. It has paid a dividend for 10+ years in a row, raised it most years, and yields over 2%. For a steady payer like this, the dividend is the best guide to value.

Business quality

4 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth8.0% a year✗

Equity per share growth12.9% a year✓

Sales growth11.9% a year✓

Free cash flow growth11.0% a year✓

Return on invested capital11.5%✓

Follow GILD

Get notified when it reaches its buy price of $45.48. Free.

Create a free account

Superinvestors

3 of the investors we track hold GILD. Who we track

Dodge & Cox Funds

Dodge & Cox Funds · as of Q2 2026

$3.0B

23,677,567 shares

John Rogers

Ariel Investments · as of Q2 2026

$24.7M

195,657 shares

Mairs & Power Funds

Mairs & Power Funds · as of Q2 2026

$287K

2,275 shares

Insider activity

Since Jun 15, 2026: no open-market purchases, 26 sales worth $15.3M and 22 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

O'Day Daniel Patrick

Chairman & CEO · 2026-09-01

Sold

$808K

O'Day Daniel Patrick

Chairman & CEO · 2026-09-01

Sold

$1.2M

O'Day Daniel Patrick

Chairman & CEO · 2026-09-01

Sold

$236K

WELTERS ANTHONY

director · 2026-08-26

Sold

$685K

WELTERS ANTHONY

director · 2026-08-26

Sold

$1.0M

Show all 26 sales

WELTERS ANTHONY

director · 2026-08-26

Sold

$462K

WELTERS ANTHONY

director · 2026-08-26

Sold

$504K

Bluestone Jeffrey

director · 2026-08-20

Sold

$167K

Bluestone Jeffrey

director · 2026-08-20

Sold

$242K

Bluestone Jeffrey

director · 2026-08-20

Sold

$263K

Bluestone Jeffrey

director · 2026-08-20

Sold

$4K

Bluestone Jeffrey

director · 2026-08-20

Sold

$49K

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-08-17

Sold

$1.6M

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-08-17

Sold

$2.3M

Dickinson Andrew D

Chief Financial Officer · 2026-08-17

Sold

$415K

O'Day Daniel Patrick

Chairman & CEO · 2026-08-03

Sold

$79K

O'Day Daniel Patrick

Chairman & CEO · 2026-08-03

Sold

$1.0M

O'Day Daniel Patrick

Chairman & CEO · 2026-08-03

Sold

$869K

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-07-15

Sold

$390K

Dickinson Andrew D

Chief Financial Officer · 2026-07-15

Sold

$390K

O'Day Daniel Patrick

Chairman & CEO · 2026-07-01

Sold

$394K

O'Day Daniel Patrick

Chairman & CEO · 2026-07-01

Sold

$1.5M

Dickinson Andrew D

Chief Financial Officer · 2026-06-15

Sold

$376K

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-06-15

Sold

$56K

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-06-15

Sold

$133K

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-06-15

Sold

$183K

Other filings

O'Day Daniel Patrick

Chairman & CEO · 2026-09-10

Tax withholding

$613K

O'Day Daniel Patrick

Chairman & CEO · 2026-09-10

Option exercise

8,780 shares

Cain Wettan Keeley M

EVP Gen Counsel, Legal & Comp · 2026-09-10

Tax withholding

$41K

Cain Wettan Keeley M

EVP Gen Counsel, Legal & Comp · 2026-09-10

Option exercise

590 shares

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-09-10

Tax withholding

$195K

Show all 22 other filings

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-09-10

Option exercise

2,797 shares

Berger Dietmar

Chief Medical Officer · 2026-09-10

Tax withholding

$38K

Berger Dietmar

Chief Medical Officer · 2026-09-10

Option exercise

533 shares

Dickinson Andrew D

Chief Financial Officer · 2026-09-10

Tax withholding

$195K

Dickinson Andrew D

Chief Financial Officer · 2026-09-10

Option exercise

2,797 shares

WELTERS ANTHONY

director · 2026-08-26

Option exercise

$468K

WELTERS ANTHONY

director · 2026-08-26

Option exercise

$631K

Bluestone Jeffrey

director · 2026-08-20

Option exercise

$315K

Bluestone Jeffrey

director · 2026-08-20

Option exercise

$2K

Bluestone Jeffrey

director · 2026-08-20

Option exercise

$79K

Bluestone Jeffrey

director · 2026-08-20

Option exercise

$21K

Bluestone Jeffrey

director · 2026-08-20

Option exercise

$112K

Bluestone Jeffrey

director · 2026-08-20

Option exercise

$122K

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-08-17

Option exercise

$1.5M

Mercier Johanna

Chief Comm & Corp Aff Officer · 2026-08-17

Option exercise

$137K

Cain Wettan Keeley M

EVP Gen Counsel, Legal & Comp · 2026-08-10

Tax withholding

$387K

Cain Wettan Keeley M

EVP Gen Counsel, Legal & Comp · 2026-08-10

Option exercise

6,002 shares

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key…

Drug Manufacturers - General

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

How we valued it

Business quality

Superinvestors

Insider activity

Sales

Other filings

About Gilead Sciences, Inc.